Form 4: Neurogene CFO Cvijic Boosts Stake with New Equity Awards

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, received new grants of restricted stock units and stock options, increasing her beneficial ownership.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc., acquired 22,000 restricted stock units (RSUs) and 131,900 stock options on February 20, 2026.
• The 22,000 RSUs will vest in three equal annual installments beginning February 20, 2027, contingent on continued service.
• The 131,900 stock options have an exercise price of $17.64 and expire on February 20, 2036.
• One quarter of the stock options will vest on February 20, 2027, with the remainder vesting in equal monthly installments over the subsequent three years.
• Following these transactions, Cvijic beneficially owns 114,643 shares of common stock and 131,900 derivative securities (stock options).
• The total beneficial ownership of common stock includes previously granted RSUs from March 13, 2024 (21,269 units remaining), March 26, 2025 (20,300 units), and the new February 20, 2026 grant (22,000 units), plus 24,000 shares held jointly with her spouse.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive commitment and alignment with shareholder interests through significant long-term equity incentives.

Positives

• Increased alignment of executive interests with shareholders through significant equity awards.
• The grants provide long-term incentives for the President and CFO, Christine Mikail Cvijic, to contribute to the company's sustained growth and performance.
• The acquisition of 22,000 restricted stock units and 131,900 stock options demonstrates confidence in the company's future.

Negatives

• No immediate cash realization for the executive from these grants, as they are subject to vesting schedules.

Risks

• The filing does not contain specific risk factors related to the company's operations or financial health. It is a disclosure of insider transactions.

Future Outlook

The equity awards are structured to incentivize long-term performance, with vesting schedules extending several years into the future, aligning the executive's compensation with the company's sustained success.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into how executives and directors are compensated and how their ownership stakes evolve. These equity grants are a common component of executive compensation packages in the biotechnology and pharmaceutical sectors, designed to align management's interests with long-term shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, particularly in growth-oriented sectors like biotechnology, frequently include substantial equity components such as restricted stock units and stock options.
• These grants are typically structured with multi-year vesting schedules to encourage long-term commitment and performance.
• While specific grant sizes vary based on company size, executive role, and performance, the structure observed here for Neurogene's President and CFO, Christine Mikail Cvijic, is consistent with common practices among peer companies in the biotech industry.
• For example, similar long-term incentive structures are seen at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals for their senior executives, aiming to retain talent and drive innovation.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Increased alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term company strategy.

Next Steps

• Vesting of 22,000 restricted stock units in three equal annual installments beginning February 20, 2027.
• Vesting of 131,900 stock options, with one quarter vesting on February 20, 2027, and the remainder vesting monthly through February 20, 2030.

Key Dates

Keywords

Neurogene Inc., NGNE, Christine Mikail Cvijic, Form 4, SEC filing, insider transaction, restricted stock units, stock options, executive compensation, beneficial ownership, corporate governance